These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 16950011

  • 1. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines.
    Hildesheim A, Markowitz L, Avila MH, Franceschi S.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/227-32. PubMed ID: 16950011
    [Abstract] [Full Text] [Related]

  • 2. Chapter 13: Current findings from prophylactic HPV vaccine trials.
    Koutsky LA, Harper DM.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/114-21. PubMed ID: 16949998
    [Abstract] [Full Text] [Related]

  • 3. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M, Jasani B, Fiander A.
    Vaccine; 2007 Apr 20; 25(16):3007-13. PubMed ID: 17292517
    [Abstract] [Full Text] [Related]

  • 4. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M, Gissmann L, Nardelli-Haefliger D.
    Vaccine; 2008 Aug 19; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [Abstract] [Full Text] [Related]

  • 5. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J, Lehtinen M.
    Ann Med; 2008 Aug 19; 40(3):162-6. PubMed ID: 18382882
    [Abstract] [Full Text] [Related]

  • 6. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E.
    Vaccine; 2007 Jun 21; 25(26):4931-9. PubMed ID: 17499406
    [Abstract] [Full Text] [Related]

  • 7. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH.
    Gynecol Oncol; 2010 Jun 21; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [Abstract] [Full Text] [Related]

  • 8. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M, Dillner J.
    J Clin Virol; 2007 Mar 21; 38(3):189-97. PubMed ID: 17258503
    [Abstract] [Full Text] [Related]

  • 9. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.
    Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA.
    Vaccine; 2007 May 22; 25(21):4324-33. PubMed ID: 17445955
    [Abstract] [Full Text] [Related]

  • 10. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
    Ault K, Reisinger K.
    Int J Infect Dis; 2007 Nov 22; 11 Suppl 2():S26-8. PubMed ID: 18162242
    [Abstract] [Full Text] [Related]

  • 11. Chapter 17: Second generation HPV vaccines to prevent cervical cancer.
    Schiller JT, Nardelli-Haefliger D.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/147-53. PubMed ID: 16950002
    [Abstract] [Full Text] [Related]

  • 12. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M, Lowy DR, Frazer I.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [Abstract] [Full Text] [Related]

  • 13. Post-licensure monitoring of HPV vaccine in the United States.
    Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF.
    Vaccine; 2010 Jul 05; 28(30):4731-7. PubMed ID: 20188681
    [Abstract] [Full Text] [Related]

  • 14. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
    Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS.
    Pediatr Infect Dis J; 2010 Feb 05; 29(2):95-101. PubMed ID: 19952863
    [Abstract] [Full Text] [Related]

  • 15. Development of prophylactic HPV vaccines.
    Gissmann L, Müller M.
    Coll Antropol; 2007 Apr 05; 31 Suppl 2():113-5. PubMed ID: 17598512
    [Abstract] [Full Text] [Related]

  • 16. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P, Henrion R, Blanc B, Girard M, Sancho-Garnier H.
    Bull Acad Natl Med; 2007 Dec 05; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [Abstract] [Full Text] [Related]

  • 17. Human papillomavirus vaccines: an update for gynecologists.
    Ault KA.
    Clin Obstet Gynecol; 2008 Sep 05; 51(3):527-32. PubMed ID: 18677145
    [Abstract] [Full Text] [Related]

  • 18. [HPV vaccination: principles, results and future perspectives].
    Rouzier R, Uzan C, Collinet P.
    J Gynecol Obstet Biol Reprod (Paris); 2007 Feb 05; 36(1):13-8. PubMed ID: 17293248
    [Abstract] [Full Text] [Related]

  • 19. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.
    Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, Smith PG.
    Vaccine; 2006 Aug 31; 24 Suppl 3():S3/233-41. PubMed ID: 16950012
    [Abstract] [Full Text] [Related]

  • 20. Prophylactic HPV vaccines: the Finnish perspective.
    Syrjänen KJ.
    Expert Rev Vaccines; 2010 Jan 31; 9(1):45-57. PubMed ID: 20021305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.